|
|
Prepublished online as a Blood First Edition Paper on August 1, 2002; DOI 10.1182/blood-2002-01-0104.
 Previous Article | Table of Contents | Next Article 
Blood, 15 December 2002, Vol. 100, No. 13, pp. 4671-4675
BRIEF REPORT
Expression of MUM1/IRF4 correlates with clinical outcome in
patients with B-cell chronic lymphocytic leukemia
Chung-Che Chang,
Jennifer Lorek,
Daniel E. Sabath,
Ying Li,
Christopher R. Chitambar,
Brent Logan,
Bal Kampalath, and
Ronald P. Cleveland
From the Department of Pathology, Division of
Hematology/Oncology, and Division of Biostatistics, Medical College of
Wisconsin, Milwaukee; Department of Laboratory Medicine, University of
Washington, Seattle; and Department of Pathology, MetroHealth Medical
Center, Case Western Reserve University, Cleveland, OH.
In this study, we evaluated the prognostic significance of multiple
myeloma-1/interferon regulatory factor-4 (MUM1/IRF4) expression in
B-cell chronic lymphocytic leukemia (B-CLL). Our results demonstrated that the absence of MUM1/IRF4 expression showed the highest relative risk among the factors analyzed in determining the probability for
death in patients with B-CLL using univariate and multivariate Cox
regression analysis. Patients without MUM1/IRF4 expression had
significantly worse overall survival than did those with MUM1/IRF4 expression (52% cumulative survival, 63 months vs not reached, Kaplan-Meier survival analysis; P < .03, log-rank test).
Patients with MUM1/IRF4 expression were more likely to have disease at low Rai stage and interstitial/nodular marrow involvement. Furthermore, only 1 of 11 patients with MUM1/IRF4 expression and
interstitial/nodular marrow involvement died during a 100-month
follow-up. Our results suggest that B-CLL with expression of MUM1/IRF4,
indicative of postgerminal center origin, has a more favorable clinical
course and that MUM1/IRF4 is an important prognostic marker in B-CLL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. A. Ramos-Vara, M. A. Miller, and V. E. O. Valli
Immunohistochemical Detection of Multiple Myeloma 1/Interferon Regulatory Factor 4 (MUM1/IRF-4) in Canine Plasmacytoma: Comparison with CD79a and CD20
Vet. Pathol.,
November 1, 2007;
44(6):
875 - 884.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Valsami, V. Pappa, D. Rontogianni, F. Kontsioti, E. Papageorgiou, J. Dervenoulas, T. Karmiris, S. Papageorgiou, N. Harhalakis, N. Xiros, et al.
A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4
Haematologica,
October 1, 2007;
92(10):
1343 - 1350.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. N. Naresh
MUM1 expression dichotomizes follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes
Haematologica,
February 1, 2007;
92(2):
267 - 268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Hoefnagel, R. Dijkman, K. Basso, P. M. Jansen, C. Hallermann, R. Willemze, C. P. Tensen, and M. H. Vermeer
Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling
Blood,
May 1, 2005;
105(9):
3671 - 3678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S E Coupland, M Hellmich, C Auw-Haedrich, W R Lee, I Anagnostopoulos, and H Stein
Plasmacellular differentiation in extranodal marginal zone B cell lymphomas of the ocular adnexa: an analysis of the neoplastic plasma cell phenotype and its prognostic significance in 136 cases
Br. J. Ophthalmol.,
March 1, 2005;
89(3):
352 - 359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
